MAP3K7 Knockout HAP1 Cell Line

The choice depends on whether you are studying MAP3K7 (TAK1)'s role as a central MAP3K in NF-κB and JNK/p38 activation downstream of TLRs, IL-1R, and TNFR signaling. The Knockout line is the standard tool for asking whether TAK1 is required for these processes — TAK1 is the principal MAP3K downstream of TAB1/TAB2/TAB3 scaffolds, activated by K63-polyubiquitination, and required for IKK-NF-κB activation and stress kinase activation in many inflammatory contexts. Overexpression is useful for studying TAK1 in heterologous expression contexts. For inflammatory signaling research, the EDITGENE MAP3K7 Knockout in HAP1 is highly informative — TAK1 is a master regulator of innate immune signaling and a validated drug target. Rescue with wild-type, kinase-dead (K63A), or TAB-binding-deficient TAK1 enables comprehensive structure-function studies. The knockout is a critical specificity control for TAK1 inhibitors (5Z-7-oxozeaenol, takinib) in inflammation and cancer drug development — TAK1 inhibition causes synthetic lethality in KRAS-mutant cancers and has emerged as a therapeutic target.

Primary applications: • NF-κB activation: phospho-IKKα/β, phospho-IκBα, and NF-κB nuclear translocation following IL-1, TNF, or TLR stimulation in TAK1-null cells. • JNK/p38 activation: phospho-JNK and phospho-p38 following inflammatory stimuli given TAK1's role as MAP3K for stress kinases. • KRAS synthetic lethality: KRAS-mutant cancer cell sensitivity to TAK1 inhibition. • TAK1 inhibitor specificity: critical genetic control for 5Z-7-oxozeaenol, takinib, and other TAK1-targeting compounds in inflammation and cancer drug development. EDITGENE recommends this model for researchers investigating TAK1-mediated innate immune signaling, KRAS-mutant cancer dependencies, and TAK1-targeted therapeutic development.

Yes. TAK1 rescue experiments are well-established for inflammatory signaling research: • Construct design: use a codon-modified MAP3K7 sequence with a small C-terminal tag (FLAG, HA). TAK1 has N-terminal kinase domain and C-terminal TAB-binding regulatory region — preserve all elements. • Kinase-dead rescue: K63A mutation in the ATP-binding lysine abolishes catalytic activity and is the standard specificity control (note: this is the K63 ATP-binding residue, not K63 of ubiquitin chains). • TAB-binding-deficient rescue: C-terminal TAB-interaction region mutations disrupt scaffolding without affecting kinase activity. • K63-polyubiquitin-binding-deficient rescue: TAB2/TAB3 partnership is required for K63-ubiquitin sensing — rescue interpretation considers TAB protein expression. • Functional readout: rescue should restore IL-1, TNF, or TLR-induced NF-κB and JNK/p38 activation. HAP1-specific considerations: • Diploidization: HAP1 cells gradually diploidize during extended culture — confirm ploidy by flow cytometry at the time of phenotypic assay. • Integration site sensitivity: position effects on transgene expression are more pronounced in near-haploid backgrounds; generating multiple independent rescue clones is strongly recommended. • Transduction efficiency: HAP1 transduces with lentivirus at moderate efficiency — increase MOI compared to standard immortalized lines.